{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:05:36Z","timestamp":1793664336118,"version":"4.5.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.leukres.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T11:57:57Z","timestamp":1556798277000},"page":"95-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Hepatitis B reactivation during treatment of tyrosine kinase inhibitors\u2014Experience in 142 adult patients with chronic myeloid leukemia"],"prefix":"10.1016","volume":"81","author":[{"given":"Yu-Hung","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Der","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-8822","authenticated-orcid":false,"given":"Chien-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2019.05.001_bib0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/10428194.2016.1219906","article-title":"Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"58","author":"Sor\u00e0","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2019.05.001_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.05.001_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.leukres.2019.05.001_bib0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"American association for the study of liver diseases. AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2019.05.001_bib0030","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","article-title":"Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with hematologic malignancies and patients who underwent hematologic stem cell transplantation-a position paper","volume":"23","author":"Sarmati","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.leukres.2019.05.001_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2019.05.001_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-009-0386-2","article-title":"Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review","volume":"90","author":"Kang","year":"2009","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0045","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3748\/wjg.v19.i8.1318","article-title":"Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor","volume":"19","author":"Lai","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0050","first-page":"112","article-title":"Hepatitis B virus reactivation under treatment with nilotinib","volume":"5","author":"Temel","year":"2015","journal-title":"Eur. J. Hepatogastroenterol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0055","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12185-015-1788-y","article-title":"Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia","volume":"102","author":"Ando","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0060","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2019.05.001_bib0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4254\/wjh.v5.i7.387","article-title":"Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: a hidden threat","volume":"5","author":"Zachou","year":"2013","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0075","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10620-006-3175-2","article-title":"Differentiating acute viral hepatitis B from the first episode of exacerbation of chronic hepatitis B","volume":"51","author":"Kumar","year":"2006","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.leukres.2019.05.001_bib0080","article-title":"High risk of hepatitis B reactivation among patients with acute myeloid leukemia","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2019.05.001_bib0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4254\/wjh.v8.i8.385","article-title":"Management of hepatitis B reactivation in immunosuppressed patients: an update on current recommendations","volume":"8","author":"Bessone","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0090","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2016.1260127","article-title":"Risk of hepatitis B reactivation under treatment with tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"58","author":"Orlandi","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2019.05.001_bib0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12876-017-0735-1","article-title":"Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.leukres.2019.05.001_bib0100","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:32Z","timestamp":1758934832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":20,"alternative-id":["S0145212619300815"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.05.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B reactivation during treatment of tyrosine kinase inhibitors\u2014Experience in 142 adult patients with chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}